Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer

被引：0
|
作者：
Marty, ME
Coombes, RC
Peckitt, C
López, FRP
Tres, A
Morvan, F
Tubiana-Mathieu, N
Espié, M
Bliss, JM
机构：
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] Inst Gustave Roussy, Villejuif, France
[3] Univ London Imperial Coll Sci Technol & Med, CR UK Labs, London, England
[4] Canc Res Inst, Sutton, Surrey, England
[5] Hosp Clin Zaragoza, Zaragoza, Spain
[6] Ctr Hosp Rene Dubos, Pontoise, France
[7] Hop Dupuytren, Limoges, France
[8] Hop St Louis, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
592
引用
收藏
页码：25S / 25S
页数：1
相关论文
共 50 条
  • [21] Adjuvant CMF (cyclophosphamide, methotrexate, fluorouracil) in breast cancer. Is it cost-effective?
    Norum, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S229 - S229
  • [22] Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer
    Davide Radice
    Alberto Redaelli
    PharmacoEconomics, 2005, 23 : 69 - 75
  • [23] Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
    H M Earl
    L Hiller
    J A Dunn
    A-L Vallier
    S J Bowden
    S D Jordan
    F Blows
    A Munro
    S Bathers
    R Grieve
    D A Spooner
    R Agrawal
    I Fernando
    A M Brunt
    S M O'Reilly
    S M Crawford
    D W Rea
    P Simmonds
    J L Mansi
    A Stanley
    K McAdam
    L Foster
    R CF Leonard
    C J Twelves
    D Cameron
    J MS Bartlett
    P Pharoah
    E Provenzano
    C Caldas
    C J Poole
    British Journal of Cancer, 2012, 107 : 1257 - 1267
  • [24] Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer
    KJ O'Byrne
    MI Koukourakis
    MP Saunders
    AJ Salisbury
    R Isaacs
    S Varcoe
    M Taylor
    TS Ganesan
    AL Harris
    DC Talbot
    British Journal of Cancer, 1998, 77 : 1950 - 1956
  • [25] Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
    Kluger, N.
    Jacot, W.
    Frouin, E.
    Rigau, V.
    Poujol, S.
    Dereure, O.
    Guillot, B.
    Romieu, G.
    Bessis, D.
    ANNALS OF ONCOLOGY, 2012, 23 (11) : 2879 - 2884
  • [26] CLINICAL CONTROLLED TRIAL IN ADVANCED BREAST-CANCER - CMF (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL) VERSUS CMF+T (CYCLOPHOSPHAMIDE, METHOTREXATE, 5-FLUOROURACIL, TAMOXIFEN)
    HINDY, I
    NEOPLASMA, 1985, 32 (03) : 381 - 387
  • [27] Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
    Earl, H. M.
    Hiller, L.
    Dunn, J. A.
    Vallier, A-L
    Bowden, S. J.
    Jordan, S. D.
    Blows, F.
    Munro, A.
    Bathers, S.
    Grieve, R.
    Spooner, D. A.
    Agrawal, R.
    Fernando, I.
    Brunt, A. M.
    O'Reilly, S. M.
    Crawford, S. M.
    Rea, D. W.
    Simmonds, P.
    Mansi, J. L.
    Stanley, A.
    McAdam, K.
    Foster, L.
    Leonard, R. C. F.
    Twelves, C. J.
    Cameron, D.
    Bartlett, J. M. S.
    Pharoah, P.
    Provenzano, E.
    Caldas, C.
    Poole, C. J.
    BRITISH JOURNAL OF CANCER, 2012, 107 (08) : 1257 - 1267
  • [28] Doxorubicin and Cyclophosphamide versus Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Adjuvant Chemotherapy in Breast Cancer
    Livi, L.
    Saieva, C.
    Borghesi, S.
    Cardillo, C. De Luca
    Scotti, V.
    Mangoni, M.
    Greto, D.
    Cataliotti, L.
    Paiar, F.
    Bianchi, S.
    Biti, G. P.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 558 - 565
  • [29] Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial
    Coombes, RC
    Bliss, JM
    Wils, J
    Morvan, F
    Espie, M
    Amadori, D
    Gambrosier, P
    Richards, M
    Aapro, M
    VillarGrimalt, A
    McArdle, C
    PerezLopez, FR
    Vassilopoulos, P
    Ferreira, EP
    Chilvers, CED
    Coombes, G
    Woods, EM
    Marty, M
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 35 - 45
  • [30] A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer
    Lindman, H.
    Andersson, M.
    Edlund, P.
    Bjerre, K. D.
    Hatschek, T.
    Mouridsen, H. T.
    Anderson, H.
    Ejlertsen, B.
    Moller, S.
    Lidbrink, E.
    Kamby, C.
    Ahlgren, J.
    Bergh, J.
    Blomqvist, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345